Summary
This paper reviews the pharmacological activity of crocin — a carotenoid glycoside found principally in saffron (Crocus sativus) — in the context of breast cancer biology. It surveys evidence relating to crocin's capacity to inhibit tumour cell proliferation, modulate inflammatory signalling, suppress angiogenesis, and enhance the efficacy of established chemotherapeutic agents. Published in PHYTONutrients, the review situates crocin within the broader field of phytonutrient-based adjunct oncology research, though the extent to which findings are drawn from in vitro, in vivo, or clinical studies is not certain from the metadata alone.
UK applicability
The findings are not specific to any national context but are relevant to UK researchers and clinicians interested in phytonutrient adjunct therapies for breast cancer, an area of growing interest within UK integrative oncology and nutritional medicine communities.
Key measures
Cell proliferation rates; inflammatory marker expression; angiogenesis indicators; drug synergism indices with standard chemotherapeutic agents
Outcomes reported
The study examined the effects of crocin, a bioactive carotenoid derived from saffron, on breast cancer cell proliferation, inflammatory pathways, angiogenic activity, and its potential synergistic action with conventional anticancer drugs.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.